411 related articles for article (PubMed ID: 27672278)
41. [Baseline analysis of refractory primary biliary cirrhosis].
Wang L; Kong F; Zhang X; Xu D; Hu ZJ; Li YZ; Zhang FC
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2918-20. PubMed ID: 23328240
[TBL] [Abstract][Full Text] [Related]
42. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
[TBL] [Abstract][Full Text] [Related]
43. Clinical evaluation of serum antimitochondrial antibody-negative primary biliary cirrhosis.
Zhang FK; Jia JD; Wang BE
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):288-91. PubMed ID: 15138128
[TBL] [Abstract][Full Text] [Related]
44. Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury.
Weber S; Benesic A; Buchholtz ML; Rotter I; Gerbes AL
Dig Dis; 2021; 39(3):275-282. PubMed ID: 32942273
[TBL] [Abstract][Full Text] [Related]
45. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Balkau B; Eschwège E; Poupon R
N Engl J Med; 1991 May; 324(22):1548-54. PubMed ID: 1674105
[TBL] [Abstract][Full Text] [Related]
46. PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody.
Arakawa Y; Amaki S; Miyakawa H; Sakai T; Gotou I; Tanaka N; Moriyama M; Iwasaki A; Sugitani M; Arakawa Y
J Gastroenterol; 2004; 39(5):490-5. PubMed ID: 15175950
[TBL] [Abstract][Full Text] [Related]
47. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis.
Granito A; Muratori P; Muratori L; Pappas G; Cassani F; Worthington J; Ferri S; Quarneti C; Cipriano V; de Molo C; Lenzi M; Chapman RW; Bianchi FB
Aliment Pharmacol Ther; 2007 Sep; 26(6):831-8. PubMed ID: 17767467
[TBL] [Abstract][Full Text] [Related]
48. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.
Rigopoulou EI; Davies ET; Pares A; Zachou K; Liaskos C; Bogdanos DP; Rodes J; Dalekos GN; Vergani D
Gut; 2005 Apr; 54(4):528-32. PubMed ID: 15753539
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis.
Bittencourt PL; Farias AQ; Abrantes-Lemos CP; Goncalves LL; Goncalves PL; Magalhães EP; Carrilho FJ; Laudanna AA; Cançado EL
J Gastroenterol Hepatol; 2004 Aug; 19(8):873-8. PubMed ID: 15242489
[TBL] [Abstract][Full Text] [Related]
50. [Liver histopathology, clinical features and prognostic factors of primary biliary cirrhosis: an analysis of 60 cases].
Yao Y; Xu ZY; Gao JP; Chen XP; Shen LJ; Yang LH; You LY; Yang JH
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):457-60. PubMed ID: 18578999
[TBL] [Abstract][Full Text] [Related]
51. [Clinical characteristics of primary biliary cirrhosis complicating Sjögren syndrome].
Gao LX; Wang L; Zhang FC
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(43):3457-9. PubMed ID: 24423911
[TBL] [Abstract][Full Text] [Related]
52. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?
Zein CO; Angulo P; Lindor KD
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):89-95. PubMed ID: 15017500
[TBL] [Abstract][Full Text] [Related]
53. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.
Nakamura M; Kondo H; Mori T; Komori A; Matsuyama M; Ito M; Takii Y; Koyabu M; Yokoyama T; Migita K; Daikoku M; Abiru S; Yatsuhashi H; Takezaki E; Masaki N; Sugi K; Honda K; Adachi H; Nishi H; Watanabe Y; Nakamura Y; Shimada M; Komatsu T; Saito A; Saoshiro T; Harada H; Sodeyama T; Hayashi S; Masumoto A; Sando T; Yamamoto T; Sakai H; Kobayashi M; Muro T; Koga M; Shums Z; Norman GL; Ishibashi H
Hepatology; 2007 Jan; 45(1):118-27. PubMed ID: 17187436
[TBL] [Abstract][Full Text] [Related]
54. Drug-induced liver injury.
Leise MD; Poterucha JJ; Talwalkar JA
Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
[TBL] [Abstract][Full Text] [Related]
55. Can the laboratory affect the investigation and diagnosis of primary biliary cirrhosis?
Sinclair D; Spedding A; Young R
J Clin Pathol; 2006 Apr; 59(4):360-2. PubMed ID: 16461570
[TBL] [Abstract][Full Text] [Related]
56. Immunostaining of plasma cells in primary biliary cirrhosis.
Daniels JA; Torbenson M; Anders RA; Boitnott JK
Am J Clin Pathol; 2009 Feb; 131(2):243-9. PubMed ID: 19141384
[TBL] [Abstract][Full Text] [Related]
57. [Primary biliary cirrhosis: clinical and epidemiological features in an Uruguayan population].
Sánchez A; Hernández N; Chiodi D; Berrueta J; Robaina G; Pollio C; Mescia G
Acta Gastroenterol Latinoam; 2013 Dec; 43(4):288-93. PubMed ID: 24516954
[TBL] [Abstract][Full Text] [Related]
58. [Clinical and pathological features of primary biliary cirrhotic patients with negative anti-mitochondria antibody].
Wang QX; Shen L; Chen XY; Qiu DK; Ma X
Zhonghua Gan Zang Bing Za Zhi; 2011 May; 19(5):340-4. PubMed ID: 21645440
[TBL] [Abstract][Full Text] [Related]
59. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis.
Harada K; Ozaki S; Gershwin ME; Nakanuma Y
Hepatology; 1997 Dec; 26(6):1399-405. PubMed ID: 9397977
[TBL] [Abstract][Full Text] [Related]
60. The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.
Duan W; Chen S; Li S; Lv T; Li B; Wang X; Wang Y; Zhao X; Ma H; Ou X; You H; Jia J
Hepatol Commun; 2022 Nov; 6(11):3112-3119. PubMed ID: 35998274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
